Newly developed strategies for improving sensitivity to radiation by targeting signal pathways in cancer therapy

Inherent and acquired resistance of cancer cells is increasingly recognized as a significant impediment to effective radiation cancer treatment. As important intracellular factors, aberrant tumor transmembrane signal transduction pathways, which include the prosurvival cascades (PI3K/Akt, MAPK/ERK and JAK/STAT) and the proapoptosis pathways (Wnt, p53 and TNF‐α/NF‐κB), have been proved to be crucial determinants of the probability of cell sensitivity to radiation in malignant lesions. There is increasing evidence that targeting the abnormal pathways that can regulate the activity of the DNA damage response and further influence the response of tumor cells to radiation may be suitable for improving radiation sensitization. Preclinical and clinical evidence suggest that agents targeting aberrant tumor signals can effectively improve the therapeutic effect of ionizing radiation. Therefore, in this review, we discuss the intricate interplay between tumor responses to radiation with the aberrant signal pathways, and the potential druggable targets within the pathways to sensitize tumors without significant collateral damage to normal tissues. The application of novel targeting compounds to manipulate the aberrant signal of tumor cells in clinical treatments is also addressed.

[1]  R. Muschel,et al.  The Ras radiation resistance pathway. , 2001, Cancer research.

[2]  J. Roth,et al.  p53 tumor suppressor gene therapy for cancer. , 1999, Oncology.

[3]  W. McBride,et al.  Inhibition of NF-κB, Clonogenicity, and Radiosensitivity of Human Cancer Cells , 1999 .

[4]  P. Elliott,et al.  Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. , 2001, International journal of radiation oncology, biology, physics.

[5]  J. Nakamura,et al.  PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas , 2005, Journal of Neuro-Oncology.

[6]  Michael Kahn,et al.  Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells? , 2010, Clinical Cancer Research.

[7]  B. Aggarwal,et al.  Role of chemopreventive agents in cancer therapy. , 2004, Cancer letters.

[8]  T. Cheng,et al.  Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy. , 2011, Drug discovery today.

[9]  Byung Hak Kim,et al.  A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells , 2008, Molecular Cancer Therapeutics.

[10]  J. Brady,et al.  Activated AKT regulates NF-κB activation, p53 inhibition and cell survival in HTLV-1-transformed cells , 2005, Oncogene.

[11]  Bernhard Schiestl,et al.  Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells , 2008, Proteomics.

[12]  M. Krause,et al.  The extreme radiosensitivity of the squamous cell carcinoma SKX is due to a defect in double-strand break repair. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  R. Schmidt-Ullrich,et al.  Stress and Radiation-Induced Activation of Multiple Intracellular Signaling Pathways1 , 2003, Radiation research.

[14]  T. Beißbarth,et al.  Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. , 2011, Carcinogenesis.

[15]  O. Stål,et al.  Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells. , 2005, International journal of oncology.

[16]  B. Joseph,et al.  Tumor radiosensitivity and apoptosis. , 1999, Experimental cell research.

[17]  Y. Miyagi,et al.  Molecular and Cellular Pathobiology Cancer Research Wnt Inhibitor Dickkopf-1 as a Target for Passive Cancer Immunotherapy , 2010 .

[18]  M. Karin,et al.  Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. , 2009 .

[19]  D. Hicklin,et al.  Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. , 2001, Cancer research.

[20]  Guang-Yuh Chiou,et al.  Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis , 2012, Journal of cellular physiology.

[21]  J. Demoulin,et al.  New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. , 2010, Blood.

[22]  J. L. Roti,et al.  Thermal Modulation of Radiation-Induced DNA Damage Responses , 2011 .

[23]  J. Mariadason,et al.  Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway. , 2010, Current cancer drug targets.

[24]  M. Milosevic.  Hypoxia, Anerobic Metabolism, and Interstitial Hypertension , 2010 .

[25]  E. Balslev,et al.  Aberrations of ERBB2 and TOP2A genes in breast cancer , 2010, Molecular Oncology.

[26]  Paul Van Houtte,et al.  NF-kappaB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. , 2006, Cancer letters.

[27]  S. Ralston,et al.  Pharmacologic inhibitors of IκB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo , 2009, Molecular Cancer Therapeutics.

[28]  Jue Hu,et al.  Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance. , 2009, Cancer treatment reviews.

[29]  D. Hallahan,et al.  Enhanced radiation damage of tumor vasculature by mTOR inhibitors , 2005, Oncogene.

[30]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[31]  L. Vassilev.  p53 Activation by small molecules: application in oncology. , 2005, Journal of medicinal chemistry.

[32]  S. Hahn,et al.  Ras inhibitors and radiation therapy. , 2001, Seminars in radiation oncology.

[33]  B. Aggarwal,et al.  Expert opinion : food for thought Back to basics : how natural products can provide the basis for new therapeutics , 2007 .

[34]  Galina Selivanova,et al.  Therapeutic targeting of p53 by small molecules. , 2010, Seminars in cancer biology.

[35]  I. Mellinghoff,et al.  AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression* , 2004, Journal of Biological Chemistry.

[36]  E. B. Butler,et al.  Radiosensitization by inhibiting STAT1 in renal cell carcinoma. , 2009, International journal of radiation oncology, biology, physics.

[37]  Sylvain Meloche,et al.  From basic research to clinical development of MEK1/2 inhibitors for cancer therapy , 2010, Journal of hematology & oncology.

[38]  S. Chuncharunee,et al.  Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand , 2010, Journal of hematology & oncology.

[39]  P. Fisher,et al.  Radiation-induced cell signaling: inside-out and outside-in , 2007, Molecular Cancer Therapeutics.

[40]  K. Rothkamm,et al.  Radiosensitization by Nitric Oxide at Low Radiation Doses , 2007, Radiation research.

[41]  A. Dicker,et al.  Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  Qiulian Wu,et al.  Cancer stem cells in glioblastoma—molecular signaling and therapeutic targeting , 2010, Protein & Cell.

[43]  Neal J Meropol,et al.  Targeting signal transduction pathways in colorectal cancer--more than skin deep. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[45]  E. Holland,et al.  DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. , 2011, Cancer research.

[46]  D. Kirsch,et al.  Tumor-suppressor p53: implications for tumor development and prognosis. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Peter M Fischer,et al.  Small-molecule inhibitors of MDM2 as new anticancer therapeutics. , 2010, Seminars in cancer biology.

[48]  P. Crooks,et al.  The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-κB inhibition and enhanced by the presence of PTEN , 2007, Molecular Cancer Therapeutics.

[49]  Michael Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[50]  C. Willey,et al.  Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[51]  D. Hallahan,et al.  Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. , 2001, Cancer research.

[52]  Do-Hyun Nam,et al.  Wnt activation is implicated in glioblastoma radioresistance , 2012, Laboratory Investigation.

[53]  H. Nakshatri,et al.  Parthenolide Sensitizes Cells to X-Ray-Induced Cell Killing through Inhibition of NF-κB and Split-Dose Repair , 2007, Radiation research.

[54]  Erica A Golemis,et al.  Selective Raf inhibition in cancer therapy , 2007, Expert opinion on therapeutic targets.

[55]  E. Wagner,et al.  Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.

[56]  Paul Dent,et al.  MAPK pathways in radiation responses , 2003, Oncogene.

[57]  I. Shiojima,et al.  Role of Akt Signaling in Vascular Homeostasis and Angiogenesis , 2002, Circulation research.

[58]  Sunil Krishnan,et al.  Targeting inflammatory pathways for tumor radiosensitization. , 2010, Biochemical pharmacology.

[59]  P. Jänne,et al.  EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  Kwok-Kin Wong,et al.  Targeting the PI3K signaling pathway in cancer. , 2010, Current opinion in genetics & development.

[61]  P. Harari,et al.  Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. , 2006, Seminars in radiation oncology.

[62]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  E. Yorke,et al.  Patient safety in external beam radiation therapy. , 2011, AJR. American journal of roentgenology.

[64]  K. W. Kim,et al.  Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation , 2006, Molecular Cancer Therapeutics.

[65]  E. Van Cutsem,et al.  Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.